Novel molecular targeted therapies for refractory thyroid cancer. [electronic resource]
- Head & neck May 2012
- 736-45 p. digital
Publication Type: Journal Article; Review
1097-0347
10.1002/hed.21755 doi
Angiogenesis Inhibitors--therapeutic use Anilides--therapeutic use Antineoplastic Agents--therapeutic use Axitinib Benzamides Benzenesulfonates--therapeutic use Benzoquinones--therapeutic use Bibenzyls--therapeutic use Boronic Acids--therapeutic use Bortezomib Depsipeptides--therapeutic use ErbB Receptors--antagonists & inhibitors Gefitinib HSP90 Heat-Shock Proteins--antagonists & inhibitors Histone Deacetylase Inhibitors--therapeutic use Humans Hydroxamic Acids--therapeutic use Imatinib Mesylate Imidazoles--therapeutic use Indazoles--therapeutic use Indoles--therapeutic use Lactams, Macrocyclic--therapeutic use Lenalidomide Niacinamide--analogs & derivatives Oligonucleotides Phenylurea Compounds--therapeutic use Piperazines--therapeutic use Piperidines--therapeutic use Protein Kinase Inhibitors--therapeutic use Protein-Tyrosine Kinases--antagonists & inhibitors Proto-Oncogene Proteins c-kit--antagonists & inhibitors Pyrazines--therapeutic use Pyridines--therapeutic use Pyrimidines--therapeutic use Pyrroles--therapeutic use Quinazolines--therapeutic use Quinolines--therapeutic use Receptor Protein-Tyrosine Kinases--antagonists & inhibitors Receptors, Vascular Endothelial Growth Factor--antagonists & inhibitors Sorafenib Sulfonamides--therapeutic use Sunitinib Thalidomide--analogs & derivatives Thyroid Neoplasms--drug therapy Valproic Acid--therapeutic use Vorinostat